COMBO-MS

Treatment tested

• Telephone-based Cognitive Behavioral Therapy
• Modafinil

  Dopamine transporter inhibitor

Other measures (3)

Inclusion Criteria: 1. Patients with clinically definite Multiple Sclerosis (MS, all MS subtypes); 2. Age 18 years or older; 3. Presence of chronic, problematic fatigue that, in the opinion of the patient, has interfered with their daily activities for ≥ 3 months; 4. Average Fatigue Severity Scale (FSS) score greater or equal to 4 at screening. Exclusion Criteria: 1. Current shift work sleep disorder, or narcolepsy diagnosed with polysomnography and multiple sleep latency test 2. History of MS relapse within the last 30 days prior to screening (participants will be considered eligible after the 30-day window); 3. Current stimulant or wake-promoting agent use (such as amantadine, modafinil, methylphenidate, or amphetamine) within 30 days of screening; 4. Pregnancy or breastfeeding; 5. Reliance on hormonal contraception AND concomitant unwillingness to use alternative non-hormonal means of birth control (spermicide or condoms) during the course of the study; 6. Current suicidal ideation (SI) with intent or plan; 7. Known hypersensitivity to modafinil or armodafinil or its inactive ingredients; 8. History of the following cardiovascular conditions: recent myocardial infarction (last 6 months prior to screening), unstable angina, left ventricular hypertrophy, mitral valve prolapse, NYHA class III or IV congestive heart failure; 9. History of prescription or illicit stimulant abuse (such as cocaine, amphetamine, methamphetamine); 10. Any other medical, neurological, or psychiatric condition that, in the opinion of the investigators, could affect participant safety or eligibility.

This clinical trial will compare the effectiveness of 3 treatments for fatigue in Multiple Sclerosis: 1) a commonly used behavioral treatment strategy (telephone-based cognitive behavioral therapy), 2) a commonly used medication (modafinil), and 3) a combination of both therapies. Each participant will receive one of these 3 treatments for a total of 12 weeks. Hypotheses are that, at 12 weeks, treatment with combination therapy will overall lead to greater reductions in fatigue impact, fatigue severity, and fatigability compared to monotherapy, and that comorbid depression, sleep disturbances, and baseline disability level will be important effect modifiers that influence treatment effect and adherence.